Interleukin-5 in the Pathophysiology of Severe Asthma

Overview

Journal Front Physiol

Date 2020 Jan 11

PMID 31920718

Citations 116

Authors

Corrado Pelaia

Giovanni Paoletti

Francesca Puggioni

Francesca Racca

Girolamo Pelaia

Giorgio Walter Canonica

Enrico Heffler

Affiliations

Soon will be listed here.

Abstract

Interleukin-5 (IL-5) exerts a central pathogenic role in differentiation, recruitment, survival, and degranulation of eosinophils. Indeed, during the last years, significant advances have been made in our understanding of the cellular and molecular mechanisms underlying the powerful actions of IL-5 finalized to the induction, maintenance, and amplification of eosinophilic inflammation. Therefore, IL-5 is a suitable target for add-on biological therapies based on either IL-5 inhibition (mepolizumab, reslizumab) or blockade of its receptor (benralizumab). These modern treatments can result in being definitely beneficial for patients with severe type 2 (T2)-high eosinophilic asthma, refractory to conventional anti-inflammatory drugs such as inhaled and even systemic corticosteroids.

Citing Articles

Chronic Inflammation in Asthma: Looking Beyond the Th2 Cell.

Olsthoorn S, van Krimpen A, Hendriks R, Stadhouders R Immunol Rev. 2025; 330(1):e70010.

PMID: 40016948 PMC: 11868696. DOI: 10.1111/imr.70010.

Narrative Review of Genetic and Immunological Mechanisms Involved in the Pathogenesis of Kimura's Disease: New Therapeutic Targets.

Loperfido A, Cavaliere C, Fionda B, Bellocchi G, Masieri S, Caminati M Genes (Basel). 2025; 16(2).

PMID: 40004521 PMC: 11855017. DOI: 10.3390/genes16020194.

Exploring Asthma as a Protective Factor in COVID-19 Outcomes.

Quinn A, Zhao L, Bell S, Huq M, Fang Y Int J Mol Sci. 2025; 26(4).

PMID: 40004141 PMC: 11855143. DOI: 10.3390/ijms26041678.

Heterogeneity and individualized therapy for eosinophilic granulomatosis with polyangiitis.

Hua L, Xie M Ther Adv Respir Dis. 2025; 19:17534666251318615.

PMID: 39980304 PMC: 11843704. DOI: 10.1177/17534666251318615.

Elevated mepolizumab levels in patients with severe asthma responsive to 1 year's mepolizumab treatment.

Nishimaki T, Sasano H, Harada S, Takeshige T, Sandhu Y, Tanabe Y J Allergy Clin Immunol Glob. 2025; 4(2):100410.

PMID: 39974310 PMC: 11836490. DOI: 10.1016/j.jacig.2025.100410.

References

Makinde T, Murphy R, Agrawal D . The regulatory role of TGF-beta in airway remodeling in asthma. Immunol Cell Biol. 2007; 85(5):348-56. DOI: 10.1038/sj.icb.7100044. View

Heffler E, Malvezzi L, Boita M, Brussino L, De Virgilio A, Ferrando M . Immunological mechanisms underlying chronic rhinosinusitis with nasal polyps. Expert Rev Clin Immunol. 2018; 14(9):731-737. DOI: 10.1080/1744666X.2018.1512407. View

Zhang J, Kuvelkar R, Murgolo N, Taremi S, Chou C, Wang P . Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5. Int Immunol. 1999; 11(12):1935-44. DOI: 10.1093/intimm/11.12.1935. View

Marichal T, Mesnil C, Bureau F . Homeostatic Eosinophils: Characteristics and Functions. Front Med (Lausanne). 2017; 4:101. PMC: 5504169. DOI: 10.3389/fmed.2017.00101. View

Kay A, Phipps S, Robinson D . A role for eosinophils in airway remodelling in asthma. Trends Immunol. 2004; 25(9):477-82. DOI: 10.1016/j.it.2004.07.006. View

Dunican E, Fahy J . Asthma and corticosteroids: time for a more precise approach to treatment. Eur Respir J. 2017; 49(6). DOI: 10.1183/13993003.01167-2017. View

Zhang X, Moilanen E, Kankaanranta H . Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone. Eur J Pharmacol. 2000; 406(3):325-32. DOI: 10.1016/s0014-2999(00)00690-7. View

Kopf M, Brombacher F, Hodgkin P, Ramsay A, Milbourne E, Dai W . IL-5-deficient mice have a developmental defect in CD5+ B-1 cells and lack eosinophilia but have normal antibody and cytotoxic T cell responses. Immunity. 1996; 4(1):15-24. DOI: 10.1016/s1074-7613(00)80294-0. View

Stirling R, van Rensen E, Barnes P, Chung K . Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma. Am J Respir Crit Care Med. 2001; 164(8 Pt 1):1403-9. DOI: 10.1164/ajrccm.164.8.2010002. View

10.

Koike M, Nakamura K, Furuya A, Iida A, Anazawa H, Takatsu K . Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity. Hum Antibodies. 2009; 18(1-2):17-27. DOI: 10.3233/HAB-2009-0198. View

11.

Johanson K, Appelbaum E, Doyle M, HENSLEY P, Zhao B, Abdel-Meguid S . Binding interactions of human interleukin 5 with its receptor alpha subunit. Large scale production, structural, and functional studies of Drosophila-expressed recombinant proteins. J Biol Chem. 1995; 270(16):9459-71. DOI: 10.1074/jbc.270.16.9459. View

12.

Uings I, McKinnon M . Development of IL-5 receptor antagonists. Curr Pharm Des. 2002; 8(20):1837-44. DOI: 10.2174/1381612023393800. View

13.

Nair P, Wenzel S, Rabe K, Bourdin A, Lugogo N, Kuna P . Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N Engl J Med. 2017; 376(25):2448-2458. DOI: 10.1056/NEJMoa1703501. View

14.

Walker J, Barlow J, McKenzie A . Innate lymphoid cells--how did we miss them?. Nat Rev Immunol. 2013; 13(2):75-87. DOI: 10.1038/nri3349. View

15.

Varricchi G, Bagnasco D, Ferrando M, Puggioni F, Passalacqua G, Canonica G . Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Ther Adv Respir Dis. 2016; 11(1):40-45. PMC: 5941977. DOI: 10.1177/1753465816673303. View

16.

Kouro T, Takatsu K . IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol. 2009; 21(12):1303-9. DOI: 10.1093/intimm/dxp102. View

17.

Castro M, Mathur S, Hargreave F, Boulet L, Xie F, Young J . Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011; 184(10):1125-32. DOI: 10.1164/rccm.201103-0396OC. View

18.

Gnanakumaran G, Suresh Babu K . Technology evaluation: mepolizumab, GlaxoSmithKline. Curr Opin Mol Ther. 2003; 5(3):321-5. View

19.

Ohnishi T, Sur S, Collins D, FISH J, Gleich G, Peters S . Eosinophil survival activity identified as interleukin-5 is associated with eosinophil recruitment and degranulation and lung injury twenty-four hours after segmental antigen lung challenge. J Allergy Clin Immunol. 1993; 92(4):607-15. DOI: 10.1016/0091-6749(93)90085-t. View

20.

Mauser P, Pitman A, Fernandez X, Foran S, Adams 3rd G, Kreutner W . Effects of an antibody to interleukin-5 in a monkey model of asthma. Am J Respir Crit Care Med. 1995; 152(2):467-72. DOI: 10.1164/ajrccm.152.2.7633694. View